Amyloid precursor protein (APP) intracellular domain (AICD) is a product of APP processing with transcriptional modulation activity, whose overexpression causes various Alzheimer's disease (AD)-related dysfunctions. Here we report that 1-(39,49-dichloro-2-fluoro[1,19-biphenyl]-4-yl)-cyclopropanecarboxylic acid) (CHF5074), a compound that favorably affects neurodegeneration, neuroinflammation and memory deficit in transgenic mouse models of AD, interacts with the AICD and impairs its nuclear activity. In neuroglioma-APPswe cells, CHF5074 shifted APP cleavage from Ab 42 to the less toxic Ab 38 peptide without affecting APP-C-terminal fragment, nor APP levels. As revealed by photoaffinity labeling, CHF5074 does not interact with c-secretase, but binds to the AICD and lowers its nuclear translocation. In vivo treatment with CHF5074 reduced AICD occupancy as well as histone H3 acetylation levels and transcriptional output of the AICD-target gene KAI1. The data provide new mechanistic insights on this compound, which is under clinical investigation for AD treatment/prevention, as well as on the contribution of the AICD to AD pathology.
T he main pathological features of Alzheimer disease (AD) are neuronal loss and the presence of neurofibrillary tangles together with senile plaques consisting of amyloid beta peptides (Ab 40 and Ab 42 ) produced by cleavage of the amyloid precursor protein (APP) in affected brain regions 1, 2 . APP processing can proceed through alternative, non-amyloidogenic or amyloidogenic pathways, initiated by either a-or b-secretase cleavage and leading to the production of two large soluble fragments (sAPPa and sAPPb) and two membrane-anchored C-terminal fragments, CTFa and CTFb, respectively. CTF processing by c-secretase generates the harmless P3 peptide (non-amyloidogenic pathway) or Ab peptides ranging in size from 35 to 42 amino acids (amyloidogenic pathway), plus the APP intracellular domain (AICD) fragment [3] [4] [5] . Gamma-secretase is a multisubunit protease that catalyzes the intramembrane processing of more than 50 type-I membrane proteins 6 . It is composed of presenilin (PS1 or PS2), the catalytic subunit responsible for CTF processing, nicastrin (Nct) and the multipass transmembrane proteins presenilin enhancer 2 (Pen-2) and anterior pharynx-defective 1 (Aph-1) 4, 5 . The amyloidogenic pathway has been shown to be the major source of AICD in vivo 7, 8 . By acting as a docking site for a heterogeneous set of adaptor proteins, the AICD has been shown to be involved in a variety of signaling processes, many of which are potentially relevant to AD pathology [9] [10] [11] . The best known AICD interactor is the adaptor protein Fe65, which stabilizes the AICD and promotes its nuclear translocation 3, 12, 13 . In the nucleus, the AICD has been reported to be present within dot-like structures also containing Fe65 and the histone acetyl-transferase Tip60 [12] [13] [14] . This multiprotein complex is involved in transcriptional activation [15] [16] [17] , though the specific role(s) of the AICD in such process, its full set of partner proteins as well as the range of genes it can target are still debated 3, 18 . The best established AICD target gene codes for the pro-apoptotic tetraspannin KAI1, also known as CD82 14, 15, 19, 20 . AICD and Fe65 overexpressing mice do not show brain Ab accumulation, yet display a number of AD-like neuropathological features, including tau hyperphosphorylation, glycogen synthase kinase-3b (GSK-3b) activation, working memory deficits and neuroinflammation 9, 21 . Because AICD levels were found to be elevated in human AD brains 9, 22 , it has been hypothesized that this C-terminal APP fragment may be causally involved in AD pathogenesis 9, 10, 23, 24 . However, small-molecules able to bind the AICD and interfere with its function(s) have not been described so far.
In various transgenic mouse models of AD, the non-steroidal antiinflammatory derivative (NSAID) CHF5074 [1-(39,49-dichloro-2-fluoro [1,19- biphenyl]-4-yl)-cyclopropanecarboxylic acid] (Fig. 1a) has been found to lower plaque burden 25 , tau hyperphosphorylation and GSK-3b levels 26 , and to reduce neuroinflammation and associated memory deficit 25, 27, 28 , thus acting simultaneously on multiple therapeutic AD targets. CHF5074 has also been shown to improve cognition and to reduce brain inflammation in ApoE4 patients with mild cognitive impairment (MCI) 29 . Similar to other NSAIDs, CHF5074 modulates c-secretase activity in vitro 30 , although this modulatory action does not translate into a measurable effect on cerebrospinal fluid (CSF) Ab levels in humans 31 .
Starting from the observation that CHF5074 lowered nuclear AICD levels in neuroglioma cells expressing the Swedish mutated form of human APP (H4swe) without inhibiting, but rather modulating, c-secretase activity, we investigated the interaction of CHF5074 with the APP substrate and the c-secretase enzyme. As revealed by photoaffinity labeling studies, CHF5074 targets the AICD region of APP-CTF without any detectable interaction with c-secretase. In addition to a lowered AICD nuclear translocation in H4swe cells, CHF5074 treatment of transgenic mice overexpressing the Swedish mutated form of human APP also markedly reduced AICD binding and H3 acetylation levels at the promoter region of the AICD target gene KAI1, with a concomitant reduction of its transcriptional output. By demonstrating for the first time the targeting of the AICD region of APP by a small-molecule compound, the data suggest a plausible mechanism that might contribute to, and explain, the broad-spectrum neuroprotective properties of CHF5074.
Results CHF5074 reduces nuclear AICD levels in H4swe cells without inhibiting c-secretase activity. H4swe cells are a human neuroglioma cell line producing the same K595N/M596L mutated form of APP expressed by the Tg2576 mouse model of AD that has been extensively utilized for the preclinical characterization of CHF-5074 25, 27, 28, 30, 32, 33 . To evaluate whether CHF5074, at concentrations (1-10 mM) that inhibit Ab 42 generation (see Supplementary Fig.  S1a ) 30 , can interfere with the nuclear translocation of the AICD, we examined AICD levels in nuclear extracts from treated and untreated H4swe cells. As shown in Fig. 1b (and Supplementary Fig. S2 ), a single band corresponding to AICD fragment was revealed by anti-APP C-terminus antibody. An 18 hour treatment caused a decrease of AICD nuclear levels, which were reduced by 60% at a CHF5074 concentration of 3 mM. To rule out a possible general inhibitory effect of CHF5074 on APP-CTF cleavage, that would also negatively affect AICD production, we analyzed APP processing in H4swe cell extracts with the use of fragment-specific antibodies recognizing different regions of the APP (see below). We found that exposure to CHF5074 (1-30 mM) for 18 hours, neither affected CTFb nor full-length-APP (FL-APP) levels, as detected in whole cell extracts by immunoblotting with the 6E10 antibody (Fig. 2a) . Similarly, no significant changes were observed in sAPPa or sAPPb levels by immunoblot analysis of conditioned cell culture media performed with the anti-APP N-terminal antibody ( Fig. 2b and Supplementary Fig. S3a ). As further shown in Fig. 2c (and Supplementary Fig. S3b ), CHF5074 also did not modify neither CTFa, nor CTFb levels, detected by immunoblot analysis of total cell extracts with the anti-APP C-terminal antibody (see Methods for details). By contrast, a significant increase of both APP-CTFs was observed under identical experimental conditions upon treatment with the c-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-Lalanyl]-S-phenylglycine t-butyl ester) (DAPT; 0.2 mM).
Although the anti-APP C-terminal antibody can also recognize the AICD, this fragment could not be detected in H4swe whole cell extracts under standard immunoreaction conditions. Instead, the AICD was detected in nuclear extracts (see Fig. 1b ), in accordance with previous data indicating that only the AICD produced at the endosome compartment (i.e., in close proximity to the nuclear compartment) can be translocated to the nucleus, thus escaping rapid cytoplasmic degradation 8 . Therefore, the unchanged levels of the APP-CTFs observed in whole extracts from CHF5074-treated cells (see Fig. 2c ) suggest that nuclear translocation, rather than c-secretase-mediated generation of the AICD, is modified by CHF5074 treatment. (1-10 mM) as indicated. A single polypeptide band immunoreactive to the anti-APP C-terminal antibody was detected in nuclear templates. Synthetic AICD-59 polypeptide (7 kDa; shown on the right) was used as a molecular mass and electrophoretic mobility reference for these experiments (upper row). Polypeptide band from the same gel was detected with an anti-histone H3 antibody (lower row). Full-length blots were presented in Supplementary Figure S2 . Data from multiple experiments are presented as bar plots derived from densitometric quantification of anti-APP C-terminal antibody immunoreactive bands (''test'') normalized with respect to the immunoreactivity signals (''control'') produced by the anti-histone H3 antibody. The test/control ratio for vehicle-treated samples was arbitrarily set to 100%; bars are the mean 6 s.e.m. of three independent experiments (*, p , 0.05; ***, p , 0.001). In accordance with previous studies 30 , ELISA analysis of secreted Ab peptides showed that CHF5074 preferentially inhibits Ab 42 compared to Ab 40 production. IC 50 values were 2.2 mM and 24 mM for Ab 42 and Ab 40 , respectively ( Supplementary Fig. S1a ). We also found that the differential effect on Ab 40 and Ab 42 levels, was accompanied by an enhanced production of the non-toxic Ab 38 peptide. The EC 50 for the stimulatory effect of CHF5074 on Ab 38 production (2.2 mM) was identical to that causing half-inhibition of Ab 42 secretion. The resulting curve was bell-shaped and peaked at a 10 mM concentration of CHF5074 ( Supplementary Fig. S1b ).
Photoaffinity labeling analysis of the CHF5074-APP interaction. Photoaffinity labeling studies, using a a photoactivatable benzophenonebiotin derivative of CHF5074 (CHF5074-BpB; Fig. 3a) , were then carried out to investigate the interaction of CHF5074 with APP-CTF and the multiprotein c-secretase complex.
As a prerequisite for this analysis, we first verified the functionality of chemically modified CHF5074-BpB. As shown in Fig. 3 , the csecretase modulation activity of CHF5074-BpB resembles that of the parent compound (see also Supplementary Fig. S1a and S1b). Compared to CHF5074, CHF5074-BpB was somewhat more potent in reducing Ab 42 than Ab 40 generation (Fig. 3b ), but retained a similar capacity to enhance Ab 38 production (Fig. 3c) . Likewise, CHF5074-BpB did not modify the cellular levels of neither the CTFs, nor FL-APP ( Fig. 3d and Supplementary Fig. S4 ), and even at high concentrations (up to 100 mM) it did not appreciably affect cell viability (Fig. 3e) .
We thus proceeded with in vitro photolabeling by incubating H4swe membrane protein fractions in the presence of CHF5074-BpB (3 mM), followed by streptavidin-mediated precipitation and immunoblot analysis using the 6E10 antibody. As shown in Fig. 4a (and Supplementary Fig. S5a ), CHF5074-BpB-cross-linked proteins bound by steptavidin beads, included FL-APP and the CTFb fragment. A lower immune-signal, especially for FL-APP, was observed when labeling was performed on whole cell lysates rather than on membrane fractions (Fig. 4a) . With both samples APP-CTF displayed a higher reactivity, which was significantly quenched (,60%) by preincubation with a 33-fold molar excess of unmodified CHF5074 ( Fig. 4b and Supplementary Fig. S5b , cf. the two right-most lanes). Importantly, parallel photolabeling/immunoblot experiments performed on H4swe membranes under both denaturing (1% Nonidet-P40 -NP40) and native conditions, using antibodies targeting four c-secretase subunits (PS1, PS2, Nct and Pen-2) did not reveal any interaction between CHF5074-BpB and the c-secretase enzyme complex (Fig. 4c) .
CHF5074 binds to the intracellular domain of APP. To gain more detailed information on the APP binding site of CHF5074, we examined CHF5074-BpB reactivity with two synthetic polypeptides corresponding to the Ab 42 and AICD-59 fragments of APP and with a recombinant glutathione S-transferase-CTFa (GSTCTFa) fusion polypeptide (see Fig. 5a ). Each polypeptide (20 pmol) was individually incubated with CHF5074-BpB (3 mM), alone and in the presence of an excess of unmodified CHF5074. As shown in Fig. 5b (upper panels) , both AICD-59 and GST-CTFa, but neither Ab 42 peptide, nor the GST carrier protein alone, were detected with IrDye-labeled streptavidin following treatment with CHF5074-BpB and the resulting signals were both quenched (,30% and 70%, respectively) by addition of the unmodified compound. Comparable results in terms of photolabeling selectivity were obtained with CHF5074-BpB concentrations as low as 0.5 mM (data not shown) and a similar lack of CHF5074-BpB reactivity with Ab was observed with monomeric ( Fig. 5b) , as well as oligomeric ( Supplementary Fig.  S6 ) Ab 42 . Altogether, the above results point to the specific binding of CHF5074 to the AICD, a C-terminal region of APP downstream to the cleavage site of c-secretase.
In vivo treatment with CHF5074 reduces AICD occupancy, histone acetylation levels and transcriptional activity of an AICD target gene. We next evaluated whether CHF5074, in addition to its lowering effect on nuclear AICD levels in a cell-based model of AD (Fig. 1b) , could also affect nuclear AICD functionality and target gene promoter occupancy in vivo. To this end, we performed a chromatin immunoprecipitation (ChIP) analysis on brain cortices from Tg2576 mice treated with either CHF5074-supplemented diet (375 ppm; <60 mg/kg/day) or standard diet for 4 weeks. The choice of this treatment protocol was based on previous preclinical data showing full reversal of recognition memory and a marked amelioration of various AD-related neuropathological features, in Tg2576 mice orally treated with the same dose of CHF5074 for 4 weeks 32 . The tetraspanin-encoding KAI1 gene, a broadly supported AICDtarget 14, 15, 20 previously subjected also to ChIP analysis 15, 20 , was used to test the effect of CHF5074 treatment. To this end, cross-linked chromatin from brain cortices of treated and untreated animals was separately immunoprecipitated with the anti-APP C-terminal antibody, an anti-acetylated histone H3 antibody, and an unrelated, control antibody. As revealed by quantitative RealTime-PCR analysis of immunoprecipitated DNA (Fig. 6a) , treatment with CHF5074 was associated to an 79% reduction of AICD occupancy and an 72% decrease of histone H3 acetylation at the KAI1 promoter. As further shown in Fig. 6b , these changes were accompanied by a significant reduction of KAI1 transcripts. These data suggest that, in addition to nuclear translocation, CHF5074 binding to the AICD interferes with nuclear transactions (i.e., promoter binding, recruitment of histone acetyl-transferase components such as Tip60 and target gene transcriptional output) mediated by the intracellular C-terminal fragment of APP.
Discussion
The main finding of this study is the peculiar ability of the antiinflammatory derivative CHF5074 to reduce nuclear translocation and activity of the APP intracellular domain by binding to the AICD peptide without altering its c-secretase-mediated generation.
In accordance with previous data 30 , CHF5074 preferentially reduced Ab 42 , compared to Ab 40 , levels and increased production of the non-toxic Ab 38 peptide in H4swe neuroglioma cells, the cellular counterpart of the Tg2576 mouse model of AD. This suggests that CHF5074 does not inhibit APP processing, but rather shifts the site of APP-CTF cleavage. Indeed, CHF5074 did not increase APP-CTF levels, as observed with the c-secretase inhibitor DAPT ( Fig. 2c ; but see also 34 ), and neither affected soluble APP fragment levels, nor the levels of FL-APP, indicating the lack of any effect on a-secretase or bsecretase activity.
Using a photoaffinity labeling approach, we found that CHF5074 binds to the AICD region of the APP-CTF substrate, but not to the csecretase complex. Binding selectivity was inferred from competition of unmodified CHF5074 on the binding of CHF5074-BpB to the AICD, which took place at concentrations 30-to 100-fold lower than those employed for photoaffinity labeling with BpB derivatives of 1 st generation c-secretase modulators 35 . In line with recent models for sequential cleavage by c-secretase 36, 37 , we hypothesize that CHF5074 binding to the AICD region of APP may influence c-secretase processivity by altering the dynamics and/or the stereochemistry of interaction between the enzyme and its substrate.
CHF5074 lowered AICD occupancy, H3 acetylation levels and transcriptional output of the target gene KAI1, suggesting that CHF5074 binding interferes not only with the nuclear translocation, but also with the nuclear activity (i.e., promoter binding and co-activator recruitment) of the AICD. The KAI1 gene codes for a proapototic tetraspanin and is one of the best established AICD targets 14, 15, 19, 20 . Indeed, neuronal apoptosis is considered a common feature of AD and the first cellular alteration that was shown to be positively regulated by the AICD 22, 38 ; an alteration that could be prevented by blocking AICD nuclear translocation 38 as well as by artificially weakening the AICD-Fe65 interaction 17 . Given the reduction of nuclear AICD levels brought about by CHF5074 and the well-known AICD-stabilizing effect of the Fe65 adaptor (reviewed by 3, 23 ), it is tempting to speculate that CHF5074 binding to APP-CTF may hinder the AICD-Fe65 interaction. This would promote cytoplasmic instability and a reduced nuclear translocation of the AICD, ultimately leading to a decreased promoter occupancy. Other, not mutually exclusive hypotheses are also possible, however. For example, interference of CHF5074 with the APP-CTF-Fe65 interaction might be sufficient to enhance cytoplasmic AICD degradation and to lower the nuclear translocation/activity of Fe65 39 . The same interaction, which involves the YENPTY region of the AICD (aa. 682-687), has been reported to promote the amyloidogenic pathway thus increasing Ab production, an effect that could be blocked by mutation (Y682G) of the AICD Tyr682 residue 40 as well as by artificial silencing of Fe65 41 . Furthermore, reversion of various neuropathological features of AD, including astrogliosis and cognitive impairment, has been reported in Tg-AD mice bearing a D664A mutation in the AICD 42 . Also notable is the overlap between the positive effects brought about by CHF5074 treatment in various transgenic mouse models of AD [25] [26] [27] [28] 32, 43 and the specific AD-related alterations associated with AICD/Fe65 overproduction. The latter, in addition to tau hyperphosphorylation/aggregation and cognitive impairment 9 , include an altered cytoskeleton dynamics 44 , impaired neurogenesis and neuroinflammation 21 . All the above alterations are reverted to varying extents and with a high degree of specificity compared to other NSAIDs, by CHF5074 [25] [26] [27] [28] 32, 43 . In addition, recent studies indicate the ability of CHF5074 to positively affect CSF biomarkers of neuroinflammation in MCI subjects 29 , further suggesting that this compound may also act as a microglial modulator capable of reducing pro-inflammatory activity, while promoting the alternative antiinflammatory and phagocytic state of microglial cells (Porrini et al., AD/PD Conference 2013).
Despite increasing evidence pointing to a causal relationship between AICD overproduction and AD, and the fact that increased AICD levels have been detected in human AD brain 9, 22 , data suggesting a beneficial role of this polypeptide, at least under certain conditions, have also been reported 45 . Moreover, another strongly supported AICD target gene, codes for the Ab-degrading enzyme neprilysin 24, 46 . Therefore, the borderline between physiological and neuropathological effects of the AICD is likely to be quite narrow and finely tuned, with a shift toward neuropathology upon massive accumulation through sustained activation of the amyloidogenic pathway.
In conclusion, the present findings provide an extended mechanistic background for the multiple effects of CHF5074. To our (1) of unmodified CHF5074 (100 mM), followed by exposure to 3 mM CHF5074-BpB. Parallel immunoblot analyses performed with the anti-APP C-terminal antibody (AICD-59), the 6E10 antibody (Ab 42 ) and with an antibody directed against GST (GST and GST-CTFa), served as controls to verify the input of the various (poly)peptides utilized for these experiments (lower panels). Cropped gel images are shown and the gels were run under the same experimental conditions. www.nature.com/scientificreports knowledge, CHF5074 is the first AICD-targeting small-molecule to be described and we believe that the availability of this compound will contribute to a better understanding of both the physiological role(s) of the AICD as well as its involvement in AD pathology.
Methods
Cell culture. H4swe were seeded at a density of 1.25 3 10 5 cells/cm 2 in 21 cm 2 culture dishes (Nunc-VWR) in Opti-MEM culture medium (Life Technologies) containing 10% fetal bovine serum and grown to confluence in a 5% CO 2 and 95% air humidified atmosphere. Cells were then incubated in Opti-MEM without serum and exposed for 18 hours to either 0.1-30 mM CHF5074 (Figure 1a ), 0.1-100 mM CHF5074-BpB (Figure 3a) or 0.2 mM DAPT (all provided by Chiesi Farmaceutici, Parma, Italy) dissolved in dimethyl sulfoxide (DMSO; 0,1% final concentration), or to the DMSO vehicle alone. The culture medium was collected and used for ELISA and cytotoxicity assays, followed by membrane and nuclear protein extraction for immunoblot/ photoaffinity labeling.
Ab measurements in H4swe culture medium. H4swe cells were exposed for 18 hours to increasing concentrations of CHF5074 (0.1-30 mM) or CHF5074-BpB (0.1-100 mM) in culture medium without serum. At the end of treatment, Ab 40 , Ab 42 and Ab 38 were measured in a fixed volume (25 ml) of culture medium supplemented with protease inhibitors (Sigma-Aldrich). Ab 40 and Ab 42 levels in the culture medium were determined with commercial ELISA kits (Life Technologies). A modification of the ELISA kit for Ab 40 was used to measure Ab 38 levels. A monoclonal antibody specific for the N-terminus of human Ab was coated onto the wells of microtiter strips. Culture medium samples were then incubated with a rabbit antibody specific for the C-termini of the 1-40, 1-42 and 1-38 Ab peptides (Covance), followed by detection of bound antibodies with a horseradish peroxidase (HRP)-conjugated antirabbit antibody.
Extract preparation and immunoblot analysis. H4swe cells were harvested in 100 ml of lysis buffer, sonicated for 30 seconds at full power (SONOPULS, titanium microtip MS-72) and centrifuged at 11,000 g for 20 minutes at 4uC. Total extracts (25 mg total protein/sample) or 25 ml of culture medium were dissolved in sample buffer and fractionated by electrophoresis on 4-12% gradient polyacrylamide-SDS gels. The anti-APP (Ab amino acids 1-16) monoclonal antibody 6E10 (SIG-39320, Covance), an anti-APP C-terminus (A8717, Sigma-Aldrich) or an anti-APP N-terminus (14-6132 eBioscience) antibody were used for detection. Antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH -MAB374, Millipore), anti-b-actin (A5060, SigmaAldrich) and anti-histone H3 (9715, Cell Signaling Technology, CST) antibodies served as loading controls.
For nuclear protein isolation, H4swe cells were scraped into 1.5 ml of ice-cold phosphate buffered saline (PBS). Cells were pelleted and resuspended in ice-cold buffer A [10 mM HEPES-KOH pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride -PMSF]. Cells were allowed to swell on ice for 10 minutes, vortexed for 10 seconds and centrifuged (18,000 g, 1 minute at 4uC). The pellet was resuspended in ice-cold buffer B (20 mM HEPES-KOH pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM PMSF) and incubated on ice for 20 minutes for high-salt extraction. Cellular debris was removed by centrifugation (18,000 g, 2 minutes at 4uC) and the supernatant was stored at 280uC. Immunoblot analysis of the AICD was performed according to 47 using the anti-APP C-terminal antibody; the synthetic AICD-59 peptide (#018-710, Phoenix Pharmaceuticals) served as a size reference and positive control for these experiments.
Cell membrane isolation. H4swe cells from a confluent 10 cm dish were collected in 500 ml of protease/phosphatase inhibitors-supplemented, ice-cold buffer C (320 mM sucrose, 1 mM HEPES, 1 mM MgCl 2 , 10 mM NaHCO 3 , pH 7.4) and sonicated.
Homogenates were centrifuged at 13,000 g for 15 minutes and membrane-containing pellets were resuspended in 300 ml of ice-cold buffer D (50 mM NaCl, 30 mM triethanolamine, 50 mM NaF, 5 mM EGTA, 5 mM EDTA, 10 mM phosphonitrophenylphosphate, 50 mM phenylarsine-oxide, 1 mM benzamide, 1 mM Nethylmaleimide, 1 mM Na-tetrathionate, 1% NP40). Membrane fractions for c-secretase analysis were also prepared under native conditions 48 by omitting the Brij-35/Lubrol WX extraction step, diluted three-fold with protease inhibitorsupplemented resuspension buffer (66.7 mM e-aminocaproic acid, 1 mM EDTA, 10 mM DTT and 50 mM BisTris-HCl, pH 7.0) and cross-linked with the photoprobe prior to detergent (NP-40) solubilization.
Photoaffinity labeling with CHF5074-BpB. Total cell lysates or membrane fractions (50 mg total protein/sample) were pre-incubated for 15 minutes at 37uC in the dark with CHF5074-BpB (3 mM; see Supplementary Methods) and then exposed to ultraviolet light (350 nm) for 30 minutes as described 35 . For competition experiments, membrane fractions were preincubated for 15 minutes with the parent compound (100 mM) prior to the addition of CHF5074-BpB. Labeled samples were analyzed by SDS-PAGE after precipitation with streptavidin magnetic beads (Thermo Fisher Scientific). After blotting and antibody reaction (6E10 mAb 15250 for full-length APP and APP-CTFb; anti-APP C-terminal antibody 15200 for APPCTFa and b), immunoreactive proteins were detected by HRP chemiluminescence (ECL-Plus, GE-Healthcare). Gamma-secretase subunits were detected with antinicastrin (151,000; Cell Signaling Technology); anti-PS1 N-terminus (15250; Santa Cruz Biotechnology) and C-terminus (151,000; CST); anti-PS2 (151,000; CST); and anti-Pen2 (diluted 151,000; CST) antibodies.
Photoaffinity labeling of isolated peptides was carried out by incubating CHF5074-BpB (3 mM), directly or after preincubation in the presence of the parent compound (100 mM), with 20 pmol of AICD-59 (Phoenix Pharmaceuticals) and Ab 42 (EZBiolab) as well as with equimolar amounts of the recombinant CTFa polypeptide (83 aa.). The latter was produced in Escherichia coli as a fusion protein with glutathione S-transferase (GST) (pGEX-4T-2 vector; GE-Healthcare) and purified/ solubilized from bacterial lysates as described 49 . After photolabeling in 50 mM MES, 0.1 M NaCl, pH 6.0 as described above, CHF5074-BpB-treated samples were fractionated by SDS-PAGE on Criterion TGX-AnykD polyacrylamide gels (BioRad) and transferred to nitrocellulose membranes by electroblotting. Following heating at 100uC in PBS for 25 seconds, membranes were blocked with 5% bovine serum albumin (BSA) in tris-buffered saline (TBS) and incubated with IrDye 680 streptavidin (diluted 153,000; LI-COR). Biotin-labeled polypeptides were visualized by nearinfrared fluorescence with an Odyssey imager as described 32 . The polypeptide input was verified in each experiment by parallel analysis of the same samples with either a rabbit anti-APP C-terminus antibody (for AICD-59), the 6E10 mAb (for Ab 42 ), or a rabbit anti-GST antibody (for GST-CTFa and GST).
Chromatin Immunoprecipitation assays. Chromatin immunoprecipitation (ChIP) assays were performed with the Magna ChIP Tissue kit (#17-20000, Millipore). Tenmonth-old Tg2576 female mice (Taconic), fed with CHF5074-supplemented (375 ppm) or standard diet (n 5 6 animals/group) were employed for these analyses. Animal care and treatments were in accordance with European Community Council directives (86/609/EEC) and in conformity with protocols approved by ethical committee for animal experimentation of University of Bologna.
Following sacrifice and brain dissection, three randomly assorted pools of entorhinal cortices from each group were frozen and chopped into small pieces. Minced tissue was cross-linked with 1.5% formaldehyde for 10 minutes at 37uC and subsequently incubated for 5 min in a 0.15 M glycine solution to stop the reaction. Cross-linked tissue was washed with ice-cold PBS and incubated on ice for 15 minutes in Tissue Lysis Buffer. Nuclei were then pelleted (800 g, 5 minutes at 4uC), resuspended in Dilution Buffer and sonicated. After centrifugation, aliquots of each chromatin sample were separately incubated with anti-APP C-terminus, anti-acetyl H3 (#07-593; Millipore) or anti-IgG (negative control) antibodies. Magnetic protein G beads were then added, followed by overnight incubation at 4uC on a rotating wheel. Another chromatin sample, not incubated with any antibody, served as input control. Antibody-captured protein/DNA complexes were washed, eluted and subjected to quantitative real-time polymerase chain reaction (qRT-PCR) analysis with the following forward (Fw) and reverse (Rev) primers: KAI1-Fw 59-ATCATG-CCATGCTGTCTGTC-39; KAI1-Rev 59-GGGCATAGGGTAGGCTGAG-39.
Immunoprecipitated DNA (2 ml/sample) was amplified in a 25 ml reaction mixture containing the SYBR Green master mix (BioRad). Real-time PCR analysis was carried out in triplicate using an iCycler (BioRad) apparatus. C T values generated by qRT-PCR analysis of samples immunoprecipitated with the anti-APP C-terminus or antiacetyl-H3 antibodies were first normalized with respect to the corresponding C T values obtained from IgG-immunoprecipitated, negative control samples, and then with respect to the relative C T values obtained from ''input'' (i.e., ''no antibody'') chromatin samples.
Transcript level determinations. Total RNA was extracted from mouse entorhinal cortices of Tg2576 mice treated with CHF5074-supplemented or standard diet as described above (n 5 3 animals/group) using the RNeasy Lipid Tissue Mini Kit (Qiagen, # 74804). RNA (1 mg/sample) was reverse-transcribed with the QuantitectH Reverse Transcription Kit (Qiagen, # 205313), using an optimized mix of oligo-dT, random primers and primer plus 73 gDNA Wipeout Buffer, and incubated at 42uC for 2 minutes to remove contaminating genomic DNA. 53 Quantiscript RT Buffer, Quantiscript Reverse Transcriptase and RT Primer Mix were then added and the reaction mixture was incubated at 42uC for 15 minutes, followed by thermal inactivation at 95uC for 3 minutes.
After cDNA synthesis, RT-PCR was carried out as described above, using the following KAI1 gene-specific primers (0.3 pmol/mL): Fw 59-TTACGTCTTCATC-GGTGTGG-39; Rev 59-CACTGTGTTCCCCATCTCCT-39. The comparative C T method was used for relative mRNA quantification; b-actin, amplified with the Fw 59-GGCTCTTTTCCAGCCTTCCT-39 and Rev 59-ATGCCTGGGTACATGGTGGT-39 primers, was used for expression level normalization.
Statistical analysis. Statistical significance of differences between groups was evaluated by two-way ANOVA and Dunnet's multiple comparison tests using the GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). ChIP data were analyzed with Student's t-tests for independent data. P-values (p) lower than 0.05 were considered as statistically significant.
